- SUANFARMA has a strong track record of successfully acquiring and integrating businesses globally
- Monteloeder is an established global leader in providing innovative, scientifically proven, botanical ingredients for dietary supplements, foods, and beverages.
- ArchiMed backs SUANFARMA to boost an ambitious industry consolidation and organic expansion, aiming to make SUANFARMA a European leader for pharma and nutraceutical ingredients.
Only three months after the entry of healthcare focused investment firm ArchiMed, SUANFARMA has reached an agreement to acquire a majority of Monteloeder, a world leader in the research and development of scientifically proven and patent-protected botanical extracts supported by clinical studies.
Monteloeder has an excellent reputation and legacy of trust in the nutraceutical and functional foods categories across the globe. Quality, science, and innovation are the three pillars of the development powerhouse, located in the Spanish Mediterranean region, with rich botanical raw materials of high value health properties.
With over 25 years in the market, Monteloeder has experienced strong international growth with a relevant presence in the USA and several Asian countries. SUANFARMA aims to expand Monteloeder's product offering into the group’s core markets and capitalize on Monteloeder’s market-leading R&D Department to strengthen the development of scientifically proven branded ingredients.
With this acquisition, SUANFARMA has taken a major step forward, significantly strengthening its development and industrial capabilities in the nutritional sector, which enriches the groups’ capabilities with its own manufacturing and development capabilities for nutraceutical ingredients. This agreement will further develop the group’s presence in areas such as weight management, cardiovascular health, nutricosmetics, and relaxation and sleep enhancement.
Both companies are committed to innovation, development, and sustainability, working on applied research that anticipates market needs, developing solutions in line with market demands based on clinical studies.
